Grazia Graziani
Grazia Graziani
Email verificata su
Citata da
Citata da
Involvement of the mismatch repair system in temozolomide-induced apoptosis
S D’Atri, L Tentori, PM Lacal, G Graziani, E Pagani, E Benincasa, ...
Molecular pharmacology 54 (2), 334-341, 1998
A region of proto-dbl essential for its transforming activity shows sequence similarity to a yeast cell cycle gene, CDC24, and the human breakpoint cluster gene, bcr.
D Ron, M Zannini, M Lewis, RB Wickner, LT Hunt, G Graziani, SR Tronick, ...
The New Biologist 3 (4), 372-379, 1991
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
E Eskilsson, GV Røsland, G Solecki, Q Wang, PN Harter, G Graziani, ...
Neuro-oncology 20 (6), 743-752, 2018
Systemic administration of GPI 15427, a novel poly (ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma …
L Tentori, C Leonetti, M Scarsella, G d’Amati, M Vergati, I Portarena, W Xu, ...
Clinical Cancer Research 9 (14), 5370-5379, 2003
Chemopotentiation by PARP inhibitors in cancer therapy
L Tentori, G Graziani
Pharmacological research 52 (1), 25-33, 2005
Potential clinical applications of poly (ADP-ribose) polymerase (PARP) inhibitors
L Tentori, I Portarena, G Graziani
Pharmacological research 45 (2), 73-85, 2002
Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid
C Ceci, PM Lacal, L Tentori, MG De Martino, R Miano, G Graziani
Nutrients 10 (11), 1756, 2018
Clinical perspectives of PARP inhibitors
G Graziani, C Szabó
Pharmacological research 52 (1), 109-118, 2005
Role of BRCA mutations in cancer treatment with poly (ADP-ribose) polymerase (PARP) inhibitors
I Faraoni, G Graziani
Cancers 10 (12), 487, 2018
Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis
L Tentori, PM Lacal, A Muzi, AS Dorio, C Leonetti, M Scarsella, F Ruffini, ...
European Journal of Cancer 43 (14), 2124-2133, 2007
Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer
G Graziani, L Tentori, P Navarra
Pharmacological research 65 (1), 9-22, 2012
Role of VEGFs/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models
C Ceci, MG Atzori, PM Lacal, G Graziani
International journal of molecular sciences 21 (4), 1388, 2020
Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive …
PM Lacal, G Graziani
Pharmacological research 136, 97-107, 2018
Role of beauty treatment in the spread of parenterally transmitted hepatitis viruses in Italy
A Mariano, A Mele, ME Tosti, A Parlato, G Gallo, P Ragni, C Zotti, ...
Journal of medical virology 74 (2), 216-220, 2004
Challenging resistance mechanisms to therapies for metastatic melanoma
L Tentori, PM Lacal, G Graziani
Trends in pharmacological sciences 34 (12), 656-666, 2013
Alternative splicing generates at least five different isoforms of the human basic-FGF receptor.
A Eisemann, JA Ahn, G Graziani, SR Tronick, D Ron
Oncogene 6 (7), 1195-1202, 1991
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy
E Salvati, M Scarsella, M Porru, A Rizzo, S Iachettini, L Tentori, G Graziani, ...
Oncogene 29 (47), 6280-6293, 2010
Inhibition of poly (ADP‐ribose) polymerase prevents irinotecan‐induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma
L Tentori, C Leonetti, M Scarsella, A Muzi, E Mazzon, M Vergati, O Forini, ...
The FASEB journal 20 (10), 1709-1711, 2006
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?
L Tentori, G Graziani
Pharmacological Research 55 (5), 359-369, 2007
Recent approaches to improve the antitumor efficacy of temozolomide
L Tentori, G Graziani
Current medicinal chemistry 16 (2), 245-257, 2009
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20